Expertise in
6
conditions

Dr. Saima M. Chohan

Rheumatology
Arizona Arthritis And Rheumatology Associates P C
10615 W Thunderbird Blvd, Suite B100, 
Sun City, AZ 
 (725.8 mi)
Accepting New Patients
Offers Telehealth
Expertise in
6
conditions
Arizona Arthritis And Rheumatology Associates P C
10615 W Thunderbird Blvd, Suite B100, 
Sun City, AZ 
 (725.8 mi)
OverviewInsuranceLocationsClinical Research

Overview

Saima Chohan is a Rheumatologist in Sun City, Arizona. Dr. Chohan is highly rated in 6 conditions, according to our data. Her top areas of expertise are Rheumatoid Arthritis (RA), Osteoporosis, Postmenopausal Osteoporosis, and Psoriatic Arthritis. Dr. Chohan is currently accepting new patients.

Her clinical research consists of co-authoring 5 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in AZ
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Medica
  •  Oscar
  •  UnitedHealthcare
  •  Humana

Locations

ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES P C
10615 W Thunderbird Blvd, Suite B100, Sun City, AZ 85351
Other Locations
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES P C
4550 E Bell Rd, Suite 170, Phoenix, AZ 85032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Active_not_recruiting
Publish Date: October 17, 2024
Intervention Type: Drug
Study Drug: HZN-825
Study Phase: Phase 2
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Enrollment Status: Completed
Publish Date: July 14, 2021
Intervention Type: Drug
Study Drug: Iloprost
Study Phase: Phase 3
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

5 Total Publications

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
Journal: Annals of the rheumatic diseases
Published: August 31, 2020
Similar Doctors
Expertise in
20
conditions
Dr. Vivek Nagaraja
Rheumatology | Geriatrics
Expertise in
20
conditions
Dr. Vivek Nagaraja
Rheumatology | Geriatrics

Mayo Clinic Arizona

5701 E Mayo Blvd, 
Phoenix, AZ 
 (19.3 mi)
480-342-4200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vivek Nagaraja is a Rheumatologist and a Geriatrics provider in Phoenix, Arizona. Dr. Nagaraja is highly rated in 20 conditions, according to our data. His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Scleroma, and Scleredema.

Expertise in
14
conditions
Dr. Lester E. Mertz
Rheumatology
Expertise in
14
conditions
Dr. Lester E. Mertz
Rheumatology

Mayo Clinic Arizona

5777 E Mayo Blvd, Mayo Clinic Hospital, 
Phoenix, AZ 
 (19.4 mi)
800-603-0558
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lester Mertz is a Rheumatologist in Phoenix, Arizona. Dr. Mertz is highly rated in 14 conditions, according to our data. His top areas of expertise are Granulomatosis with Polyangiitis, Microscopic Polyangiitis, Necrotizing Vasculitis, and Dermatomyositis.

Expertise in
23
conditions
Dr. Kenneth G. Lawlor
Rheumatology
Expertise in
23
conditions
Dr. Kenneth G. Lawlor
Rheumatology

Kenneth G. Lawlor, Do, PLLC

2060 W Whispering Wind Dr, Suite 264, 
Phoenix, AZ 
 (12.6 mi)
623-235-6889
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kenneth Lawlor is a Rheumatologist in Phoenix, Arizona. Dr. Lawlor is highly rated in 23 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Psoriasis, Sjogren Syndrome, and Psoriatic Arthritis. Dr. Lawlor is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile